Skip to main content

Despite huge progress in prevention and treatment over the past 50 years, cardiovascular disease remains New Zealand’s number one killer.

This is because our population is getting older and we are increasingly suffering from comorbidities associated with heart disease such as diabetes, obesity and high blood pressure. Premature death and disability are still, today, devastating consequences of heart disease and stroke.

Cardiovascular disease is also the costliest disease in terms of hospital admissions and health care delivery. Investing in scientific research for the prevention and treatment of cardiovascular disease is therefore vital for our health, and vital for the economic viability of our health care sector.

The core mission of the HRI – to improve our understanding of the causes and complications of cardiovascular disease – therefore remains essential.

The HRI is growing and facing an exciting future, underpinned by a strong history of scientific excellence. I encourage you to share in the sense of excitement and discovery that HRI research brings.

Professor Len Kritharides
Chairman, Board of Governors, HRI

Financial Statement

The Heart Research Institute has a strong balance sheet and a solid asset base. This is important for smoothing any fluctuations in income in any single year and for enabling our scientific staff to have greater security of tenure.

HRI is currently fundraising in three international markets: Australia, New Zealand, and the United Kingdom.